Patents by Inventor Hamida Hammad

Hamida Hammad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GALECTIN-10 ANTIBODIES
    Publication number: 20240026010
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: June 7, 2023
    Publication date: January 25, 2024
    Inventors: Jean-Michel PERCIER, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Galectin-10 antibodies
    Patent number: 11713354
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 1, 2023
    Assignees: ARGENX BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • GALECTIN-10 ANTIBODIES
    Publication number: 20210332140
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: March 8, 2021
    Publication date: October 28, 2021
    Inventors: Jean-Michel PERCIER, Christophe BLANCHETOT, Michael SAUNDERS, Hans DE HAARD, Sebastian VAN DER WONING, Emma PERSSON, Bart LAMBRECHT, Savvas SAVVIDES, Hamida HAMMAD, Kenneth VERSTRAETE
  • Galectin-10 antibodies
    Patent number: 11066473
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 20, 2021
    Assignees: argenx IIP BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • IL-33R and IL-1RAcP fusion proteins
    Patent number: 10703799
    Abstract: The present invention relates to novel inhibitors of IL-33. More specifically, it relates to a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP as inhibitor of IL-33 activity. The invention relates further to the use of the inhibitor in treatment of IL-33-related diseases such as, but not limited to, asthma, atopic dermatitis and psoriasis.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: July 7, 2020
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Rudi Beyaert, Harald Braun, Bart Lambrecht, Hamida Hammad
  • GALECTIN-10 ANTIBODIES
    Publication number: 20190367619
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: April 12, 2019
    Publication date: December 5, 2019
    Inventors: Jean-Michel PERCIER, Christophe BLANCHETOT, Michael SAUNDERS, Hans DE HAARD, Sebastian VAN DER WONING, Emma PERSSON, Bart LAMBRECHT, Savvas SAVVIDES, Hamida HAMMAD, Kenneth VERSTRAETE
  • NOVEL INTERLEUKIN-33 INHIBITORS
    Publication number: 20150315262
    Abstract: The present invention relates to novel inhibitors of IL-33. More specifically, it relates to a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP as inhibitor of IL-33 activity. The invention relates further to the use of the inhibitor in treatment of IL-33-related diseases such as, but not limited to, asthma, atopic dermatitis and psoriasis.
    Type: Application
    Filed: December 10, 2013
    Publication date: November 5, 2015
    Inventors: Rudi Beyaert, Harald Braun, Bart Lambrecht, Hamida Hammad